Baxter’s Bloomington facility to fill vials of Moderna’s COVID-19 vaccine
Bloomington, IN – Another Bloomington facility will be producing COVID-19 vaccines.
Baxter International Inc. recently announced a deal with Moderna to produce 60-90 million doses of COVID-19 vaccines by year’s end. Baxter BioPharma Solutions will provide fill/finish sterile manufacturing services and supply packaging from its Bloomington facilities. Catalent is also producing Moderna’s COVID-19 vaccine at its Bloomington facilities.
Baxter’s BioPharma Solutions business is a contract manufacturing organization specializing in injectable pharmaceuticals, including vaccines, according to a news release from the company. The site has capabilities and expertise in injectable delivery systems as well as clinical and commercial vaccine manufacturing.
Baxter BioPharma Solutions has operated in Bloomington for about 20 years and employs more than 700 people on its 600,000-square-foot campus.“We welcome the opportunity to work with Baxter BioPharma Solutions on fill/finish manufacturing for the Moderna COVID-19 Vaccine in the U.S.,” said Juan Andres, Moderna’s chief technical operations and quality officer, in the release. “This additional production will help us continue to scale up our manufacturing capacity in the United States.”
Additional details of the agreement were not disclosed.